Related references
Note: Only part of the references are listed.Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
Emmanuel S. Antonarakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy
Joseph Marascio et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
Wassim Abida et al.
CLINICAL CANCER RESEARCH (2020)
Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline
Scott E. Eggener et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort
Daniel W. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Transcriptome profiling of NRG Oncology/RTOG 9601: Validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial.
Felix Y Feng et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
Joaquin Mateo et al.
LANCET ONCOLOGY (2020)
Independent Evaluation of the Respective Predictive Values for High-Grade Prostate Cancer of Clinical Information and RNA Biomarkers after Upfront MRI and Image-Guided Biopsies
Mathieu Roumiguie et al.
CANCERS (2020)
Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy
Alejandro Berlin et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2019)
Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2
Baris Turkbey et al.
EUROPEAN UROLOGY (2019)
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Bringing Prostate Cancer Germline Genetics into Clinical Practice
Sanjay Das et al.
JOURNAL OF UROLOGY (2019)
Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines
Piper Nicolosi et al.
JAMA ONCOLOGY (2019)
Genomic correlates of clinical outcome in advanced prostate cancer
Wassim Abida et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer
Vincenza Conteduca et al.
EUROPEAN JOURNAL OF CANCER (2019)
Tumour lineage shapes BRCA-mediated phenotypes
Philip Jonsson et al.
NATURE (2019)
Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers
Elizabeth C. Page et al.
EUROPEAN UROLOGY (2019)
846PDPreliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses
W Abida et al.
ANNALS OF ONCOLOGY (2019)
LBA12_PRPROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations
M Hussain et al.
ANNALS OF ONCOLOGY (2019)
LBA50Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)
M R Smith et al.
ANNALS OF ONCOLOGY (2019)
Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency
Zafeiris Zafeiriou et al.
EUROPEAN UROLOGY (2019)
Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer
Anis A. Humid et al.
EUROPEAN UROLOGY (2019)
PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer
Elena Castro et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study
Olivier Rouviere et al.
LANCET ONCOLOGY (2019)
Genomics of lethal prostate cancer at diagnosis and castration resistance
Joaquin Mateo et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance
Hyung L. Kim et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2019)
Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
Wassim Abida et al.
JAMA ONCOLOGY (2019)
TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer
Bram De Laere et al.
CLINICAL CANCER RESEARCH (2019)
Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer
Frank-Jan H. Drost et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2019)
The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential
Peter Strom et al.
EUROPEAN UROLOGY (2018)
Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide
Emmanuel S. Antonarakis et al.
EUROPEAN UROLOGY (2018)
Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study
Joaquin Mateo et al.
EUROPEAN UROLOGY (2018)
Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017
Veda N. Giri et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection
Peter H. Carroll et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
The long tail of oncogenic drivers in prostate cancer
Joshua Armenia et al.
NATURE GENETICS (2018)
Clinical implications of PTEN loss in prostate cancer
Tamara Jamaspishvili et al.
NATURE REVIEWS UROLOGY (2018)
MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis
V Kasivisvanathan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
Matti Annala et al.
CANCER DISCOVERY (2018)
NICE Advice - Prolaris gene expression assay for assessing long-term risk of prostate cancer progression: © NICE (2016) Prolaris gene expression assay for assessing long-term risk of prostate cancer progression
[Anonymous]
BJU INTERNATIONAL (2018)
Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10 ng/ml at Initial Biopsy
James McKiernan et al.
EUROPEAN UROLOGY (2018)
Optimizing patient's selection for prostate biopsy: A single institution experience with multi-parametric MRI and the 4Kscore test for the detection of aggressive prostate cancer
Sanoj Punnen et al.
PLOS ONE (2018)
Genome-Based Classification and Therapy of Prostate Cancer
Arlou Kristina Angeles et al.
DIAGNOSTICS (2018)
Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer
Howard I. Scher et al.
EUROPEAN UROLOGY (2017)
Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer
Matti Annala et al.
EUROPEAN UROLOGY (2017)
Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores
Julie Lecarpentier et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model
Deepansh Dalela et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration- Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide
Emmanuel S. Antonarakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease
Daniel E. Spratt et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Risk Stratification by Urinary Prostate Cancer Gene 3 Testing Before Magnetic Resonance Imaging-Ultrasound Fusion-targeted Prostate Biopsy Among Men With No History of Biopsy
Michael Fenstermaker et al.
UROLOGY (2017)
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Jane Goodall et al.
CANCER DISCOVERY (2017)
The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer
Mark M. Pomerantz et al.
CANCER (2017)
Prognostic correlation of cell cycle progression score and Ki-67 as a predictor of aggressiveness, biochemical failure, and mortality in men with high-risk prostate cancer treated with external beam radiation therapy
Ivan Henruquez Lopez et al.
REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY (2017)
Decipher Test Impacts Decision Making Among Patients Considering Adjuvant and Salvage Treatment After Radical Prostatectomy: Interim Results From the Multicenter Prospective PRO-IMPACT Study
John L. Gore et al.
CANCER (2017)
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
V. Conteduca et al.
ANNALS OF ONCOLOGY (2017)
The Cognitive and Behavioral Phenotypes of Individuals with CHRNA7 Duplications
M. A. Gillentine et al.
JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS (2017)
Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making
Wassim Abida et al.
JCO PRECISION ONCOLOGY (2017)
The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years
Martin Boegemann et al.
BJU INTERNATIONAL (2016)
A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer
Thomas U. Ahearn et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer
Thomas U. Ahearn et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment
Scott A. Tomlins et al.
EUROPEAN UROLOGY (2016)
Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score
Leander Van Neste et al.
EUROPEAN UROLOGY (2016)
Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer
Heather H. Cheng et al.
EUROPEAN UROLOGY (2016)
Familial Risk and Heritability of Cancer Among Twins in Nordic Countries
Lorelei A. Mucci et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Prostate Cancer Early Detection, Version 2.2016
Peter R. Carroll et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2016)
Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis
Shuang G. Zhao et al.
LANCET ONCOLOGY (2016)
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
C. C. Pritchard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies
Leander Van Neste et al.
PROSTATE (2016)
A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy
James McKiernan et al.
JAMA ONCOLOGY (2016)
Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort
J. Cuzick et al.
BRITISH JOURNAL OF CANCER (2015)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
The Molecular Taxonomy of Primary Prostate Cancer
Adam Abeshouse et al.
CELL (2015)
Development and Clinical Validation of an In Situ Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer
Peter Blume-Jensen et al.
CLINICAL CANCER RESEARCH (2015)
A Multi-institutional Prospective Trial in the USA Confirms that the 4Kscore Accurately Identifies Men with High-grade Prostate Cancer
Dipen J. Parekh et al.
EUROPEAN UROLOGY (2015)
Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer
Elena Castro et al.
EUROPEAN UROLOGY (2015)
Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer
Tobias Nordstrom et al.
EUROPEAN UROLOGY (2015)
A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer
Jennifer Cullen et al.
EUROPEAN UROLOGY (2015)
Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naive Men
Claire de la Calle et al.
JOURNAL OF UROLOGY (2015)
PROSTATE CANCER Predicting prostate biopsy results-PCA3 versus phi
Stacy Loeb
NATURE REVIEWS UROLOGY (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result
M. J. Donovan et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2015)
Plasma AR and abiraterone-resistant prostate cancer
Alessandro Romanel et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Emmanuel S. Antonarakis et al.
JAMA ONCOLOGY (2015)
Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error
M. Shipitsin et al.
BRITISH JOURNAL OF CANCER (2014)
The multiple layers of non-genetic regulation of PTEN tumour suppressor activity
Nadia C. Correia et al.
EUROPEAN JOURNAL OF CANCER (2014)
A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling
Eric A. Klein et al.
EUROPEAN UROLOGY (2014)
Prospective Multicentre Evaluation of PCA3 and TMPRSS2-ERG Gene Fusions as Diagnostic and Prognostic Urinary Biomarkers for Prostate Cancer
Gisele H. J. M. Leyten et al.
EUROPEAN UROLOGY (2014)
Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy
Robert B. Den et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Tumor clone dynamics in lethal prostate cancer
Suzanne Carreira et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer
Colin C. Pritchard et al.
NATURE COMMUNICATIONS (2014)
The Prostate Health Index: a new test for the detection of prostate cancer
Stacy Loeb et al.
THERAPEUTIC ADVANCES IN UROLOGY (2014)
Prognostic Utility of Cell Cycle Progression Score in Men With Prostate Cancer After Primary External Beam Radiation Therapy
Stephen J. Freedland et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
DNA Mismatch Repair in Prostate Cancer
Himisha Beltran
JOURNAL OF CLINICAL ONCOLOGY (2013)
Validation of a Cell-Cycle Progression Gene Panel to Improve Risk Stratification in a Contemporary Prostatectomy Cohort
Matthew R. Cooperberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer
Elena Castro et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
PCA3 Molecular Urine Test as a Predictor of Repeat Prostate Biopsy Outcome in Men with Previous Negative Biopsies: A Prospective Multicenter Clinical Study
Marc C. Gittelman et al.
JOURNAL OF UROLOGY (2013)
The role of BRCA1 and BRCA2 in prostate cancer
Elena Castro et al.
ASIAN JOURNAL OF ANDROLOGY (2012)
Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort
J. Cuzick et al.
BRITISH JOURNAL OF CANCER (2012)
Germline BRCA1 mutations increase prostate cancer risk
D. Leongamornlert et al.
BRITISH JOURNAL OF CANCER (2012)
The mutational landscape of lethal castration-resistant prostate cancer
Catherine S. Grasso et al.
NATURE (2012)
Germline Mutations in HOXB13 and Prostate-Cancer Risk
Charles M. Ewing et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Plasma-Derived Exosomal Survivin, a Plausible Biomarker for Early Detection of Prostate Cancer
Salma Khan et al.
PLOS ONE (2012)
BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients
Z. Kote-Jarai et al.
BRITISH JOURNAL OF CANCER (2011)
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
Brett S. Carver et al.
CANCER CELL (2011)
Decreased Prostate Cancer-Specific Survival of Men with BRCA2 Mutations from Multiple Breast Cancer Families
Heather Thorne et al.
CANCER PREVENTION RESEARCH (2011)
PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients
Tamara L. Lotan et al.
CLINICAL CANCER RESEARCH (2011)
Exosomes as Biomarker Treasure Chests for Prostate Cancer
Diederick Duijvesz et al.
EUROPEAN UROLOGY (2011)
Common Gene Rearrangements in Prostate Cancer
Mark A. Rubin et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study
Jack Cuzick et al.
LANCET ONCOLOGY (2011)
Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA
Scott A. Tomlins et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Prostate cancer incidence trends in Spain before and during the prostate-specific antigen era: impact on mortality
N. Larranaga et al.
ANNALS OF ONCOLOGY (2010)
Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer
David J. Gallagher et al.
CLINICAL CANCER RESEARCH (2010)
Mortality results from the Goteborg randomised population-based prostate-cancer screening trial
Jonas Hugosson et al.
LANCET ONCOLOGY (2010)
Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer
J. Nilsson et al.
BRITISH JOURNAL OF CANCER (2009)
Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer
Gerhardt Attard et al.
CANCER RESEARCH (2009)
Screening and Prostate-Cancer Mortality in a Randomized European Study
Fritz H. Schroeder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Rapid progression of prostate cancer in men with a BRCA2 mutation
S. A. Narod et al.
BRITISH JOURNAL OF CANCER (2008)
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer
Scott A. Tomlins et al.
NATURE (2007)
Under diagnosis and over diagnosis of prostate cancer
Theresa Graif et al.
JOURNAL OF UROLOGY (2007)
PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy
Leonard S. Marks et al.
UROLOGY (2007)
Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells
Hadi Valadi et al.
NATURE CELL BIOLOGY (2007)
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer
SA Tomlins et al.
CANCER RESEARCH (2006)
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
SA Tomlins et al.
SCIENCE (2005)
Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome
G Petrovics et al.
ONCOGENE (2005)
Share Paper
